Updated:
XClinical GmbH
XClinical GmbH is a Munich-based firm with no disclosed AUM, principals, or strategy — making institutional evaluation difficult due to public opacity.
XClinical GmbH
XClinical GmbH is registered in Munich, Germany, but no founding year, named principals, or wealth origin are confirmed in public records. The name overlaps with a clinical-trial software vendor, XClinical, founded in 2004 by Dr. Ralf-Peter Ryseck — making the investment entity's identity ambiguous. The firm's strategy and deployment are not disclosed. No asset-class mix, portfolio companies, deal co-investors, or geographic footprint are available in public sources. This lack of transparency limits institutional assessment. No team size, additional offices, or affiliated vehicles are documented. No recent operational events are verifiable, leaving a gap in current posture evaluation. Without disclosed structure or funding patterns, XClinical GmbH's differentiation is unknowable. The firm's opacity suggests a private mandate or early-stage setup with minimal public footprint — a material constraint for due diligence.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Munich, Germany
Sector focus
Frequently asked questions
Who runs investment decisions at XClinical GmbH?
No named principals or investment leaders are publicly identified for XClinical GmbH. The entity's leadership is distinct from the clinical-trial software company XClinical AG, which was led by Dr. Ralf-Peter Ryseck as CEO. Institutional allocators would need direct engagement to clarify decision-making authority.
Is XClinical GmbH the same as the clinical-trial software vendor?
The name overlap with XClinical AG, a software company focused on electronic data capture for clinical trials, creates ambiguity. XClinical GmbH may be a separate corporate entity for investment activities or wealth management. Confirm the legal registration and any structural ties with the firm before committing capital.
What investment strategy does XClinical GmbH follow?
No public information describes XClinical GmbH's investment strategy. The firm does not disclose sector focus, asset-class allocation, stage preferences, or deal structures. Prospective partners should request a strategy memorandum or regulatory filings to assess deployment approach.
Does XClinical GmbH manage external capital or operate as a family office?
There are no public records specifying whether XClinical GmbH manages third-party capital or operates as a single-family office. Registered as a GmbH (limited liability company) in Germany, it could be a corporate vehicle for holding assets. Verification via German commercial register (Handelsregister) is advised.
What is the AUM of XClinical GmbH?
AUM is not disclosed. No public filings, press reports, or marketing materials provide a figure. Until the firm publishes AUM or regulatory filings, it remains classified as Undisclosed.
Where does the underlying wealth for XClinical GmbH come from?
The wealth origin is not disclosed. The firm does not tie its capital to a specific family, fortune, or corporate cash flow. The lack of wealth-origin transparency is a due diligence concern.
How does XClinical GmbH source deals or partnerships?
No sourcing model or deal-flow process is publicly known. The firm may rely on direct relationships or operate as a passive holding entity. Patience is required — this information is only available through direct outreach.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: